 Shares of Adamis Pharmaceuticals Corp. ADMP, 2.73 soared 20.4 on massive volume toward an eight-month high in premarket trading Monday, after the biopharmaceutical company said Zimhi, its high-dose naloxone injection for the treatment for opioid overdose, has been approved by the Food and Drug Administration. Trading volume spiked to 32.8 million shares, enough to make the stock the most actively traded ahead of the open, and compared with the full-day average of about 2.0 million shares. 